- Home
- RVT vs GENB Comparison
RVT vs GENB Comparison
Compare RVT & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RVT | GENB |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | RVT | GENB |
|---|---|---|
| Price | $16.71 | $13.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 250.8K | ★ 969.5K |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.97 | $11.00 |
| 52 Week High | $19.12 | $22.67 |
Technical Indicators
Market Signals| Indicator | RVT | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 46.20 |
| Support Level | $15.84 | $11.82 |
| Resistance Level | $18.63 | $14.29 |
| Average True Range (ATR) | 0.28 | 1.00 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 27.96 | 21.24 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.